And in ADDITION....Lu-PSMA improves outcomes in mHSPC | With Scott Tagawa and Michael Hofman

Hot off the press in the Presidential Plenary at #ESMO25, we chat with Dr Scott Tagawa (Weill-Cornell, USA) about the positive data he just presented from the PSMAddition trial. This is an eagerly awaited phase III randmosied trial of patients with mHSPC, to see if the addition of six cycles of Lu-PSMA-617 to a control arm of ADT and an ARPI, could improve rPFS and other endpoints. We are also joined in the studio by Prof Michael Hofman (Peter MacCallum Cancer Centre, AUS), co-PI of the UpFront PSMA trial which also explored a similar concept, plus some comments from our other colleague, prof Arun Azad, who was the Discussant in the Presidential at ESMO25. Declan Murphy hosting GU Cast solo today while Renu Eapen was in the OR doing surgery.

This is a Themed Podcast supported by our Silver Partners, Novartis.

Also available as an audio podcast - just search GU Cast wherever you get your podcasts, or play directly below